Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Lyme disease, or Lyme borreliosis, is a multisystem bacterial infection caused by pathogenic members of the Borrelia burgdorferi sensu lato complex and transmitted predominantly through the bite of infected Ixodes ticks. The United States reports more than 80,000 cases annually through national surveillance, while claims-based analyses indicate that the number of people diagnosed and treated may be considerably higher. According to Lyme Disease Epidemiology Forecast by Expert Market Research (EMR), Lyme disease epidemiology is difficult to compare directly between countries because notification systems capture different clinical and laboratory definitions.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Lyme Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Lyme Disease. It projects the future incidence and prevalence rates of Lyme Disease cases across various populations. The study covers age, gender, and type as major determinants of the Lyme Disease population. The report highlights patterns in the prevalence of Lyme Disease over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Lyme Disease in the 8 major markets.
Regions Covered
Lyme disease, or Lyme borreliosis, is a multisystem bacterial infection caused by pathogenic members of the Borrelia burgdorferi sensu lato complex and transmitted predominantly through the bite of infected Ixodes ticks. Clinical disease ranges from localized erythema migrans to early disseminated neurological or cardiac disease and later musculoskeletal manifestations, particularly Lyme arthritis. The epidemiological burden is concentrated in geographically suitable tick habitats, and surveillance systems substantially differ between countries.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Country |
Germany |
|
High-Risk Population |
People with frequent exposure to Ixodes ticks, including outdoor workers, forestry and agricultural workers, hikers and residents of endemic rural or wooded areas; children and older adults can also show elevated incidence in several datasets. |
|
Key Diagnostic Method |
Clinical assessment supported by two-tier serologic testing using an initial immunoassay followed by a second-tier immunoblot or equivalent validated assay; erythema migrans can be diagnosed clinically without laboratory confirmation in appropriate epidemiological settings. |
|
Major Risk Factor |
Exposure to infected Ixodes ticks, particularly during outdoor activity in endemic areas; risk is influenced by tick distribution, habitat, seasonality and human behavior. |
|
Major gap in the market |
Underdiagnosis and diagnostic heterogeneity remain important gaps because early infection may be seronegative, erythema migrans may be absent or unrecognized, and serological assays differ in sensitivity and antigen composition. |
The Lyme Disease epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Lyme Disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Lyme Disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
Lyme disease does not have a stable global point-prevalence estimate suitable for the 8MM because infection is geographically focal and surveillance largely measures incident diagnoses. The U.S. CDC estimates >80,000 reported cases annually and approximately 476,000 diagnosed/treated cases annually from claims data; France estimated 35,147 primary-care cases in 2024; Germany recorded 138,107 newly diagnosed patients in 2024 among continuously observed statutory-insurance beneficiaries. |
|
Gender-Specific Cases of the Disease |
Sex distribution varies by population and manifestation. In the UK, the 2025 laboratory-confirmed acute incidence was 1.95/100,000 in males and 1.88/100,000 in females. Japan's national surveillance analysis found 62% of reported cases were male. A U.S. Medicaid/Medicare analysis found substantial differences by age and insurance population rather than a uniform sex pattern. |
|
Age-Specific Cases of the Disease |
Lyme disease occurs across age groups, with incidence commonly elevated in children and older adults. German claims data identified incidence peaks among children aged 5-9 years and older adults. U.S. Medicare beneficiaries ≥65 years had the highest incidence in the analysed Medicare population. Japan's national surveillance had a median age of 53 years. |
|
Ethnicity-Wise Cases of the Disease |
U.S. administrative data show that most identified cases occurred among people identifying as White, ranging from 85.0% among Medicaid beneficiaries >19 years to 96.6% among Medicare beneficiaries >65 years in the 2016–2021 analysis. These figures reflect the demographic composition and geographic distribution of diagnosed populations and should not be interpreted as evidence of intrinsic ethnic susceptibility. |
|
Mortality and Survival Analysis of the Disease |
Mortality is uncommon but can occur with severe neurological, cardiac or disseminated disease. Japan's national surveillance study identified no fatal cases among 265 reported cases. Germany recorded 15 deaths attributed to Lyme disease in 2024, alongside approximately 4,830 Lyme-related hospital treatments. |
|
Disease Type |
Prevalence |
|
Early Localized Lyme Disease |
Characterized predominantly by erythema migrans at the site of infection, with possible constitutional symptoms such as fever, fatigue and headache. |
|
Early Disseminated Lyme Disease |
Occurs when Borrelia disseminates beyond the initial inoculation site and may produce multiple erythema migrans lesions, neurological involvement or cardiac manifestations. |
|
Lyme Neuroborreliosis |
Neurological Lyme disease involving peripheral or central nervous system structures, including meningoradiculitis, cranial neuropathy and other inflammatory neurological syndromes. |
|
Lyme Carditis |
Cardiac involvement associated with Lyme disease, most characteristically producing atrioventricular conduction abnormalities but potentially involving other cardiac manifestations. |

Read more about this report - Request a Free Sample
The Lyme Disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
CDC currently reports more than 80,000 Lyme disease cases annually through national surveillance. A separate insurance-claims analysis estimates approximately 476,000 people are diagnosed and treated each year, although CDC cautions that billing codes can overestimate confirmed disease. Approximately 90% of reported cases historically arise from 15 high-incidence jurisdictions in the Northeast, mid-Atlantic and upper Midwest. |
|
Germany |
A 2024 analysis by the Zentralinstitut für die kassenärztliche Versorgung identified 138,107 people with a first Lyme borreliosis diagnosis in statutory-insurance claims in 2024, equivalent to 221 newly diagnosed patients per 100,000 insured persons. Rates were particularly high in eastern Germany and Bavaria, with Saxony reaching 361/100,000 and North Rhine at 116/100,000. |
|
France |
Santé publique France estimated 35,147 Lyme borreliosis cases diagnosed in primary care in 2024, corresponding to 53/100,000 inhabitants (95% CI 43–63). The 2023 estimate was 39,052 cases and 59/100,000. Hospital surveillance recorded 633 Lyme disease admissions in 2024. |
|
Italy |
Italy lacks a directly comparable national contemporary incidence series. A prospective single-centre study conducted from March 2024 to January 2025 enrolled 93 people following tick exposure; Borrelia spp. was detected in 7.5% of tick pools and two participants were confirmed with Lyme borreliosis. Contemporary Italian evidence therefore demonstrates ongoing transmission but does not provide a national population estimate. |
|
Spain |
Lyme borreliosis remains geographically focal, with Asturias representing an important clinical focus. A 2024 publication analysing 2009-2022 hospital records identified 38 active neuroborreliosis cases among 51 active Lyme disease episodes after exclusion of diagnostic or coding errors. A 2025 systematic review of Spanish tick studies estimated B. burgdorferi sensu lato prevalence in Ixodes ricinus at 5.9%, providing an entomological rather than human-incidence measure. |
|
United Kingdom |
England reported 1,168 laboratory-confirmed acute Lyme disease cases in 2025, including 134 acute neurological cases, compared with 959 in 2024 and 1,151 in 2023. The 2025 acute laboratory-confirmed rate was 1.99/100,000. UKHSA notes that laboratory surveillance underestimates total acute disease because clinically diagnosed erythema migrans does not require laboratory confirmation. |
|
Japan |
National surveillance recorded 265 Lyme disease cases from fiscal years 2006-2023, including 216 domestic and 43 imported cases; 28 cases were reported in 2023. Domestic notification rates had a median of 0.94 per 10 million population annually. Most domestic cases occurred in Hokkaido, 62% were male, median age was 53 years, and no fatal cases were reported. |
|
India |
Recent evidence indicates that Lyme borreliosis has been reported across multiple states in India, although comprehensive national epidemiological data remain limited. Available serological studies have also identified evidence of exposure to Borrelia burgdorferi in selected regions, supporting the presence of Lyme borreliosis in parts of the country. |
The Lyme disease epidemiological landscape across the 8MM reflects diverse surveillance approaches and an expanding evidence base. While countries use different reporting systems and data sources, these collectively provide valuable insights into disease patterns and patient populations. In India, growing evidence from regional clinical reports and serological studies indicates the presence of Lyme borreliosis across multiple regions. Emerging surveillance initiatives and increasing research activity are contributing to a better understanding of its geographic distribution and epidemiological characteristics. Continued generation of regional and national evidence is expected to further strengthen disease surveillance, support identification of affected populations, and improve the characterization of Lyme borreliosis across the country.
The management of Lyme Disease has shifted from prevention and lifestyle counseling alone toward chronic, multidisciplinary disease management. The 2023 American Academy of Pediatrics guideline recommends intensive health behavior and lifestyle treatment, ideally providing at least 26 contact hours of family-based, multicomponent intervention over 3-12 months. Pharmacotherapy should be offered to adolescents aged 12 years and older with obesity when clinically indicated, alongside lifestyle treatment, while adolescents aged 13 years and older with severe obesity should be referred for evaluation for metabolic and bariatric surgery. Contemporary pharmacological treatment includes GLP-1 receptor agonists such as liraglutide and semaglutide, phentermine/topiramate, and other age-appropriate therapies. Recent research continues to evaluate long-term safety, durability, and treatment options.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.